JPS6129930B2 - - Google Patents
Info
- Publication number
- JPS6129930B2 JPS6129930B2 JP17476083A JP17476083A JPS6129930B2 JP S6129930 B2 JPS6129930 B2 JP S6129930B2 JP 17476083 A JP17476083 A JP 17476083A JP 17476083 A JP17476083 A JP 17476083A JP S6129930 B2 JPS6129930 B2 JP S6129930B2
- Authority
- JP
- Japan
- Prior art keywords
- oil
- triacetin
- mixed oil
- antitumor agent
- dissolved
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000003921 oil Substances 0.000 claims description 60
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 claims description 60
- 239000001087 glyceryl triacetate Substances 0.000 claims description 30
- 235000013773 glyceryl triacetate Nutrition 0.000 claims description 30
- 229960002622 triacetin Drugs 0.000 claims description 30
- 239000002246 antineoplastic agent Substances 0.000 claims description 23
- 238000010438 heat treatment Methods 0.000 claims description 19
- 239000008157 edible vegetable oil Substances 0.000 claims description 13
- 229960002949 fluorouracil Drugs 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 4
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 12
- 235000010445 lecithin Nutrition 0.000 description 12
- 229940067606 lecithin Drugs 0.000 description 12
- 239000000787 lecithin Substances 0.000 description 12
- 230000000694 effects Effects 0.000 description 10
- 238000001953 recrystallisation Methods 0.000 description 9
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 8
- 210000004881 tumor cell Anatomy 0.000 description 8
- 239000013078 crystal Substances 0.000 description 7
- 238000005481 NMR spectroscopy Methods 0.000 description 6
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 6
- 230000007062 hydrolysis Effects 0.000 description 6
- 238000006460 hydrolysis reaction Methods 0.000 description 6
- 239000011261 inert gas Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 229910052805 deuterium Inorganic materials 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 4
- 229960004618 prednisone Drugs 0.000 description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 3
- 230000001093 anti-cancer Effects 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- IBSQPLPBRSHTTG-UHFFFAOYSA-N 1-chloro-2-methylbenzene Chemical compound CC1=CC=CC=C1Cl IBSQPLPBRSHTTG-UHFFFAOYSA-N 0.000 description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 230000004727 humoral immunity Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- WFWLQNSHRPWKFK-ZCFIWIBFSA-N tegafur Chemical compound O=C1NC(=O)C(F)=CN1[C@@H]1OCCC1 WFWLQNSHRPWKFK-ZCFIWIBFSA-N 0.000 description 2
- 229960001674 tegafur Drugs 0.000 description 2
- OVGDAVVFKDPXIC-UHFFFAOYSA-N 1-acetyl-5-fluoropyrimidine-2,4-dione Chemical compound CC(=O)N1C=C(F)C(=O)NC1=O OVGDAVVFKDPXIC-UHFFFAOYSA-N 0.000 description 1
- QHLJWFQTGRWJRP-UHFFFAOYSA-N 6-acetyl-5-fluoro-1H-pyrimidine-2,4-dione Chemical compound CC(=O)c1[nH]c(=O)[nH]c(=O)c1F QHLJWFQTGRWJRP-UHFFFAOYSA-N 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 238000005979 thermal decomposition reaction Methods 0.000 description 1
- 125000003944 tolyl group Chemical group 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP17476083A JPS6064917A (ja) | 1983-09-21 | 1983-09-21 | 抗腫瘍剤及びその製造法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP17476083A JPS6064917A (ja) | 1983-09-21 | 1983-09-21 | 抗腫瘍剤及びその製造法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPS6064917A JPS6064917A (ja) | 1985-04-13 |
JPS6129930B2 true JPS6129930B2 (de) | 1986-07-10 |
Family
ID=15984191
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP17476083A Granted JPS6064917A (ja) | 1983-09-21 | 1983-09-21 | 抗腫瘍剤及びその製造法 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPS6064917A (de) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS61277622A (ja) * | 1985-05-31 | 1986-12-08 | Teijin Ltd | 活性型ビタミンd3類製剤用組成物 |
NZ234802A (en) * | 1989-08-14 | 1992-11-25 | Merck & Co Inc | Long acting injectable formulations comprising an avermectin compound and triacetin. treatment for internal and external parasites of animals |
JP6001845B2 (ja) | 2011-11-30 | 2016-10-05 | 株式会社アマダホールディングス | 製品保管方法,製品保管装置,加工システム,及び被保管製品の製造方法 |
-
1983
- 1983-09-21 JP JP17476083A patent/JPS6064917A/ja active Granted
Also Published As
Publication number | Publication date |
---|---|
JPS6064917A (ja) | 1985-04-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Rose | Synthesis of Cephalin1 | |
EP0228612B1 (de) | Alpha, alpha-Trehalose-Derivat und Verfahren zur Herstellung davon | |
JP2000511203A (ja) | ピラジン化合物 | |
DE2414680C2 (de) | Substituierte 2-Furancarbonsäuren und 2-Furancarbonsäureester, Verfahren zu ihrer Herstellung und Arzneimittel, die diese Verbindungen enthalten | |
DE2845496A1 (de) | N hoch 2 -substituierte phenyl-2,6- diaminonebularine und sie enthaltende arzneimittelzubereitungen | |
JPH0528239B2 (de) | ||
US2447715A (en) | Esters of diacyl-glycerophosphoric acids | |
JPS6129930B2 (de) | ||
KR20070040781A (ko) | Ⅶa 인자 억제제 | |
US4127671A (en) | P-acetamidophenyl diethylaminoacetate | |
SU799662A3 (ru) | Способ получени производныхбЕНзОилМОчЕВиНы | |
JPS5918399B2 (ja) | 有機ゲルマニウム重合体の製造方法 | |
JP2909279B2 (ja) | ホスファチジルコリン誘導体の製法 | |
JPH08193050A (ja) | 9,10− ジオキソアントラセン−2− カルボン酸誘導体及び該化合物を含む組成物 | |
CH433378A (de) | Verfahren zur Herstellung neuer Anthranilsäurederivate | |
CA1175856A (en) | 4-bis(phenylmethyl)amino)benzenesulfonic acids, virus inhibiting compositions containing them and method for inhibiting viruses | |
JPH0656840A (ja) | デポー製剤 | |
CN1012815B (zh) | 制备偕-二卤代-和四卤代-1,12-二氨基-4,9-二氮杂-十二烷的方法 | |
CN100352822C (zh) | 硫代磷酰胺类杀虫剂的衍生物 | |
CN1438217A (zh) | 一种抗生育化合物及其制备方法 | |
US3703544A (en) | Process for preparing the tris(hydroxymethyl)-aminomethane salt of pge2 | |
JPS6036411A (ja) | 抗腫瘍剤及びその製造法 | |
JPS5857368A (ja) | 置換ピリミド−2−オン化合物 | |
JPS6056981A (ja) | 1−(2−ヒドロキシエチル)−5−置換−1H−ピラゾロ〔3,4−b〕ピラジン誘導体及び該化合物を含有する抗腫瘍剤 | |
US4062975A (en) | Amino substituted arylthio-alkanoic acids having hypolipidemic activity |